Showing results (121-130 of 143) with videos related to
Sort By:
Pageof 15
JAMA Network Open|November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving NivolumabMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.Frontiers in Oncology|October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysisSara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.Pageof 15